^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD205-targeted antibody-drug conjugate

    Related drugs:
    25d
    AdCC_2023-01: Study of OBT076 Associated or Not in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck (clinicaltrials.gov)
    P1, N=19, Completed, Groupe Oncologie Radiotherapie Tete et Cou | Suspended --> Completed | N=32 --> 19 | Trial completion date: Sep 2027 --> Oct 2024 | Trial primary completion date: Sep 2026 --> Oct 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    balstilimab (AGEN2034) • OBT076
    5ms
    AdCC_2023-01: Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck (clinicaltrials.gov)
    P1, N=32, Suspended, Groupe Oncologie Radiotherapie Tete et Cou | Recruiting --> Suspended
    Trial suspension • IO biomarker • Metastases
    |
    balstilimab (AGEN2034) • OBT076
    1year
    Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors (clinicaltrials.gov)
    P1, N=200, Recruiting, Oxford BioTherapeutics Ltd | N=150 --> 200 | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    LY75 (Lymphocyte Antigen 75)
    |
    CD20 positive
    |
    OBT076
    over1year
    AdCC_2023-01: Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Groupe Oncologie Radiotherapie Tete et Cou
    New P1 trial • IO biomarker • Metastases
    |
    balstilimab (AGEN2034) • OBT076
    almost3years
    Potential novel Immuno-oncology mechanism revealed during translational phase I Immuno-blood profiling of experimental ADC medicine OBT076 in a gastric cancer patient (AACR 2022)
    Here we report on a potential novel immuno-oncology mechanism revealed during the Translational Phase I (NCT04064359) immuno-blood profiling of a chemo-refractory patient treated with OBT076, an experimental CD205-directed ADC.A chemo-refractory advanced gastric cancer patient with 60% CD205 expression in the primary tumor via IHC and having previously undergone 2 lines of chemotherapy treatment (Docetaxel/cisplatin/5FU and Ramucirumab/Paclitaxel), received five 21-day cycles of OBT076 (one at 2.5mg/kg and four cycles at 2.0 mg/kg) followed by 1 cycle of Pembrolizumab (PZ; 200mg) ~4 weeks later...These findings suggest that OBT076 activates the patient’s immune response against the tumor through a potentially novel mechanism: drug-induced depletion of CD8+ CD205+ immuno-suppressive cells and subsequent T-cell activation. Additionally, our data support the use of immune checkpoint inhibitors in conjunction with OBT076 to achieve favorable clinical outcomes.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    Keytruda (pembrolizumab) • cisplatin • paclitaxel • docetaxel • 5-fluorouracil • Cyramza (ramucirumab) • OBT076
    over4years
    Precision medicine for human cancers with Notch signaling dysregulation (Review). (PubMed, Int J Mol Med)
    Small‑molecule γ‑secretase inhibitors (AL101, MRK‑560, nirogacestat and others) and antibody‑based biologics targeting Notch ligands or receptors [ABT‑165, AMG 119, rovalpituzumab tesirine (Rova‑T) and others] have been developed as investigational drugs...Phase III clinical trials of Rova‑T for patients with small‑cell lung cancer and a phase III clinical trial of nirogacestat for patients with desmoid tumors are ongoing. Integration of human intelligence, cognitive computing and explainable artificial intelligence is necessary to construct a Notch‑related knowledge‑base and optimize Notch‑targeted therapy for patients with cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • FLT3 (Fms-related tyrosine kinase 3) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • NOTCH1 (Notch 1) • FGFR (Fibroblast Growth Factor Receptor) • CD19 (CD19 Molecule) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CCND1 (Cyclin D1) • CD79B (CD79b Molecule) • HGF (Hepatocyte growth factor) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF17 (TNF Receptor Superfamily Member 17) • NOTCH2 (Notch 2) • DLL3 (Delta Like Canonical Notch Ligand 3) • CD44 (CD44 Molecule) • NOTCH3 (Notch Receptor 3) • NOTCH4 (Notch 4) • RAC1 (Rac Family Small GTPase 1) • BMI1 (BMI1 proto-oncogene, polycomb ring finger) • FGF (Fibroblast Growth Factor) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    NOTCH1 mutation
    |
    Rova-T (rovalpituzumab tesirine) • Ogsiveo (nirogacestat) • AL101 • AMG 119 • dilpacimab (ABT-165)